Truxima (Rituximab-abbs Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 2, 2020 Category: Drugs & Pharmacology Source Type: news

Switching From Rituximab to Biosimilar CT-P10 in RA Switching From Rituximab to Biosimilar CT-P10 in RA
CT-P10, a biosimilar of reference rituximab, may be a safe and effective treatment option for patients with rheumatoid arthritis.Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 20, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Amgen and Allergan submit Biologics License Application for ABP 798, biosimilar candidate to Rituxan ® (rituximab)
Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 798, a biosimilar candidate to Rituxan® (rituximab). Amgen and Allergan are collaborating on four oncology biosimilar medicines, two of which have already been approved by the FDA. (Source: World Pharma News)
Source: World Pharma News - December 19, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

John M. Pagel, MD, PhD, on Polatuzumab Vedotin
The Swedish Cancer Center expert discussed the addition of polatuzumab vedotin to a bendamustine-rituximab regimen at the ASH Annual Meeting& Exposition. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2019 Category: Cancer & Oncology Authors: John M. Pagel, MD, PhD Source Type: news

IMBRUVICA ® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukemia
· Follow-up data from Phase 3 E1912 study (Abstract #33) evaluating the investigational use of IMBRUVICA® in combination with rituximab versus fludarabine, cyclophosphamide and rituximab showed statistically significant difference in progression-free survival (PFS) and overall survival (OS) were m aintained in previously untreated patients (ages 70 or younger) with chronic lymphocytic leukemia (CLL)· Integrated analysis from RESONATETM and RESONATETM-2 studies in CLL (Abstract #3054) reported long-term PFS, OS and response rates with earlier treatment with IMBRUVICA® · IMBRUVICA® plus ven etoclax data from Phase 2 CA...
Source: Johnson and Johnson - December 9, 2019 Category: Pharmaceuticals Source Type: news

Ibrutinib/Rituximab Combo Induced Superior PFS in Older Patients with CLL
The combination of ibrutinib and rituximab demonstrated superior progression-free survival in older patients with previously untreated chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - December 9, 2019 Category: Cancer & Oncology Authors: Wayne Kuznar Source Type: news

Lenalidomide/Rituximab Combo Improves PFS in Subgroup of Patients with NHL
Treatment with lenalidomide and rituximab improved progression-free survival, compared with placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - December 9, 2019 Category: Cancer & Oncology Authors: Gina Columbus Source Type: news

CHMP recommends conditional EU approval of Roche ’s Polivy for people with previously treated aggressive lymphoma
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Polivy ® (polatuzumab vedotin) in combination with bendamustine plus MabThera® (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not candidates for a haematopoietic stem cell transplant. (Source: Roche Media News)
Source: Roche Media News - November 15, 2019 Category: Pharmaceuticals Source Type: news

CHMP recommends conditional EU approval of Roche ’s Polivy for people with previously treated aggressive lymphoma
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Polivy ® (polatuzumab vedotin) in combination with bendamustine plus MabThera® (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not candidates for a haematopoietic stem cell transplant. (Source: Roche Investor Update)
Source: Roche Investor Update - November 15, 2019 Category: Pharmaceuticals Source Type: news

Penn uncovers dose of medication more likely to put patients with pemphigus into remission
(University of Pennsylvania School of Medicine) Researchers from Penn compare a lymphoma-dose regimen of rituximab to a rheumatoid arthritis regimen for the treatment of pemphigus. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 11, 2019 Category: International Medicine & Public Health Source Type: news

Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Supplemental New Drug Application -- submitted through FDA Real-Time Oncology Review program -- is based on positive Phase 3 data in patients aged 70 or younger RARITAN, N.J., Nov. 8, 2019 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharma... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, Johnson & Johnson, IMBRUVICA, ibrutinib (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 8, 2019 Category: Pharmaceuticals Source Type: news

Phase III PEMPHIX study shows Roche ’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris
Roche today announced data from the Phase III PEMPHIX study evaluating the efficacy and safety of MabThera ®/Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV). (Source: Roche Media News)
Source: Roche Media News - October 14, 2019 Category: Pharmaceuticals Source Type: news

Phase III PEMPHIX study shows Roche ’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris
Roche today announced data from the Phase III PEMPHIX study evaluating the efficacy and safety of MabThera ®/Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV). (Source: Roche Investor Update)
Source: Roche Investor Update - October 14, 2019 Category: Pharmaceuticals Source Type: news

Different Infection Risks for MS Treatments Different Infection Risks for MS Treatments
New study results suggest rituximab has a higher risk of serious infections than fingolimod or natalizumab, but a lower risk of herpetic infections.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 10, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Humira, Rituxan Top List of U.S. Drugs With Biggest Price Increases -report Humira, Rituxan Top List of U.S. Drugs With Biggest Price Increases -report
Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 10, 2019 Category: Infectious Diseases Tags: Public Health & Prevention News Source Type: news